In Brief: Phenylpropanolamine
This article was originally published in The Tan Sheet
Executive Summary
Phenylpropanolamine: FDA has agreed to investigate assertions by Spray-U-Thin phenylpropanolamine weight-loss spray manufacturer Caprice-Greystoke of a potential conflict of interest involving FDA Office of OTC Drug Evaluation Director Michael Weintraub, MD, who conducted a study for Acutrim maker Ciba Consumer in 1986 on time-release PPA capsules six years before joining FDA. Caprice-Greystoke claims FDA reversed its position on time-release PPA after Weintraub became director of the OTC office. FDA recently told the firm that Weintraub has disqualified himself from the decision-making process on the efficacy of PPA for weight control ("The Tan Sheet" Aug. 7, p. 13)...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
People In Brief
Perrigo promotes in pricing, planning
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: